ClinicalTrials.gg
Not yet recruitingNCT07605468GLOVEUpdated Nov 18, 2026

Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension

An interventional study of Low glycemic Mediterranean diet behavioral modification in Age-Related Macular Degeneration, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Planned enrollment
315th of 491
32 · median 55
Started
2027
with 2 others
No phase
78 of 645
15 open now
Primary completion
2028-06
later than 82 of 124 live
Registered
635th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 315th largest by planned enrollment of the 491 interventional ones that give a count, is one of 3 that started in 2027, is one of 78 with no phase, reaches primary completion later than 82 of the 124 other live ones, and was the 635th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The primary goal of the study is to test dietary intervention at glycemic control and carotenoid levels in participants with intermediate age-related macular degeneration.

03

Conditions studied

  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of early to intermediate AMD with no history of retinal geographic atrophy (cRORA) or exudative disease
  • Eating a diet less healthy than average (Healthy Eating Index [HEI] score \<61) based on 3 24-hour dietary recalls
  • Access to a computer or smart phone for use in the behavioral meetings (we will provide loaners for those lacking a smart phone
  • Because the initial questionnaires (ASA24), surveys and will be on line and in English, only individuals with fluency in English will be included. (They do not need to list English as their primary language.)

Exclusion criteria

Exclusion Criteria:

  • greater than 6.5%,
  • Diabetes or medications used to treat diabetes or obesity (including GLP1 agonists, metformin, glyburide
  • Use of statins, niacin or other lipid/cholesterol modifying medications
  • Recent cancer (within past 3 years)
  • Other retinal or ocular pathology (other than pseudophakia and/or refractive error (between -8 to +8 diopter spherical equivalence)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    low glycemic Mediterranean diet behavioral modification

    Participants receive recommendations to modify their diets to be low glycemic and adhere to Mediterranean diet Participants wear continuous glucose monitors for 2 weeks for one year.

    Behavioral: Low glycemic Mediterranean diet behavioral modification

Interventions

  • BehavioralLow glycemic Mediterranean diet behavioral modification

    Participants will meet with behavioral interventionists to receive guidance on diet initially for 2 hours and then every month for one hour

06

What researchers measure

Primary outcomes

  1. Success rate of the diet behavioral modification

    Success rate of the behavioral modification of the diet based on self-reported assessments and in association with systemic markers of improved health due to dietary modifications. Continuous glucose monitoring measurements will be used to determine the proportion of time glucose \>140 mg/dL for 24 hr/day for two weeks at each visit. The definition of success will be halving the time glucose is \>140 mg/dL.

    Time frame: baseline through one year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — data will be shared among UCLA, Dartmouth, Tufts and Stanford

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 5 years

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Jun 2028, 12 months later.

Of 105 non-industry interventional studies with no phase under Macular Degeneration, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 12 months is below that.

Counting every sponsor, half of 133 studies reached it within 37 months; a quarter within 17 and three quarters within 60.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 26, 2026
StartEst.
Jun 2027was Jun 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Jun 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Jun 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07605468
Responsible party
Mary Elizabeth Hartnett (Professor of Ophthalmology, Stanford University) — Principal investigator
First posted
May 26, 2026
Start date
Jun 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Mary E Hartnett, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion